CHARLES SCHWAB INVESTMENT MANAGEMENT INC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 1 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2020$7,000
-50.0%
18,6400.0%0.00%
Q2 2020$14,000
+100.0%
18,6400.0%0.00%
Q1 2020$7,000
-50.0%
18,6400.0%0.00%
Q4 2019$14,000
+7.7%
18,6400.0%0.00%
Q3 2019$13,000
-58.1%
18,6400.0%0.00%
Q2 2019$31,000
-34.0%
18,6400.0%0.00%
Q1 2019$47,00018,6400.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Novo Holdings A/S 1,280,185$9,755,0001.01%
Cormorant Asset Management, LP 201,000$1,532,0000.24%
PUTNAM INVESTMENTS LLC 575,692$4,386,0000.01%
Alyeska Investment Group, L.P. 114,113$870,0000.01%
VANGUARD GROUP INC 4,355,424$131,473,0000.01%
BLACKROCK ADVISORS LLC 463,200$3,530,0000.00%
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 26,100$199,000,0000.00%
Ironwood Financial, llc 870$7,0000.00%
PANAGORA ASSET MANAGEMENT INC 24,293$185,0000.00%
Sonora Investment Management, LLC 500$3,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders